Metformina + Sitagliptina Ratiopharm (Metformin Hydrochloride, Sitagliptin)

Metformin works by decreasing hepatic glucose production and increasing peripheral insulin sensitivity. Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4, prolonging the action of incretin hormones that stimulate insulin release and suppress glucagon secretion in a glucose‑dependent manner. Together they target two distinct pathways to lower blood sugar.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for the combination in pregnancy are limited, and it is generally recommended to avoid use unless the potential benefit justifies the risk. Metformin may be used in certain pregnancy situations, but sitagliptin lacks sufficient data. Breastfeeding mothers should consult their physician, as the drug may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with metformin monotherapy, the addition of sitagliptin offers greater HbA1c reduction without the weight gain associated with some other agents like sulfonylureas. Unlike insulin, it does not cause hypoglycaemia when used alone, and it provides a convenient oral fixed‑dose option versus injectable GLP‑1 receptor agonists.

Store the tablets at temperatures below 25 °C in their original packaging, protecting them from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not use the product after the expiry date printed on the label.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and maintain consistent timing each day.

Serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, especially in patients with renal impairment or severe hypoxia. Additionally, sitagliptin has been associated with pancreatitis and severe hypersensitivity reactions. Prompt medical attention is required if symptoms such as unexplained muscle pain, abdominal pain, or rash develop.

Patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and those with a history of lactic acidosis should avoid this medication. It is also contraindicated in individuals with acute or chronic metabolic acidosis, including diabetic ketoacidosis.